Docosahexaenoic acid modifies the clustering and size of lipid rafts and the lateral organization and surface expression of MHC class I of EL4 cells.
An emerging molecular mechanism by which docosahexaenoic acid (DHA) exerts its effects is modification of lipid raft organization. The biophysical model, based on studies with liposomes, shows that DHA avoids lipid rafts because of steric incompatibility between DHA and cholesterol. The model predicts that DHA does not directly modify rafts; rather, it incorporates into nonrafts to modify the lateral organization and/or conformation of membrane proteins, such as the major histocompatibility complex (MHC) class I. Here, we tested predictions of the model at a cellular level by incorporating oleic acid, eicosapentaenoic acid (EPA), and DHA, compared with a bovine serum albumin (BSA) control, into the membranes of EL4 cells. Quantitative microscopy showed that DHA, but not EPA, treatment, relative to the BSA control diminished lipid raft clustering and increased their size. Approximately 30% of DHA was incorporated directly into rafts without changing the distribution of cholesterol between rafts and nonrafts. Quantification of fluorescence colocalization images showed that DHA selectively altered MHC class I lateral organization by increasing the fraction of the nonraft protein into rafts compared with BSA. Both DHA and EPA treatments increased antibody binding to MHC class I compared with BSA. Antibody titration showed that DHA and EPA did not change MHC I conformation but increased total surface levels relative to BSA. Taken together, our findings are not in agreement with the biophysical model. Therefore, we propose a model that reconciles contradictory viewpoints from biophysical and cellular studies to explain how DHA modifies lipid rafts on several length scales. Our study supports the notion that rafts are an important target of DHA's mode of action.
Shaikh
Saame Raza
SR
Department of Biochemistry and Molecular Biology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA. shaikhsa@ecu.edu
Rockett
Benjamin Drew
BD
Salameh
Muhammad
M
Carraway
Kristen
K
D000818:Animals; D000906:Antibodies / Q000378:metabolism; D001402:B-Lymphocytes; D002417:Cattle; D002460:Cell Line; D002462:Cell Membrane / Q000737:chemistry / Q000187:drug effects* / Q000502:physiology; D002784:Cholesterol / Q000032:analysis; D004281:Docosahexaenoic Acids / Q000032:analysis / Q000494:pharmacology*; D015118:Eicosapentaenoic Acid / Q000032:analysis / Q000494:pharmacology; D008051:Lipid Bilayers / Q000737:chemistry*; D008285:Major Histocompatibility Complex / Q000187:drug effects* / Q000502:physiology; D021962:Membrane Microdomains / Q000737:chemistry / Q000187:drug effects* / Q000502:physiology; D008565:Membrane Proteins / Q000378:metabolism*; D051379:Mice; D008954:Models, Biological; D019301:Oleic Acid / Q000032:analysis / Q000494:pharmacology; D011487:Protein Conformation / Q000187:drug effects; D012710:Serum Albumin, Bovine / Q000032:analysis / Q000494:pharmacology; D013395:Sucrose
D000906:Antibodies; D008051:Lipid Bilayers; D008565:Membrane Proteins; D004281:Docosahexaenoic Acids; D012710:Serum Albumin, Bovine; D019301:Oleic Acid; D013395:Sucrose; D002784:Cholesterol; D015118:Eicosapentaenoic Acid